Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A pilot study of continuous infusional 5-fluorouracil 200 mg m(-2) per 24 h by ambulatory pump and Hickman line for the entire treatment cycle with mitomycin C 8 mg m(-2) i.v. on day 1 and cisplatin 75 i.v. on day 1, both repeated every 28 days, was carried out in 31 previously untreated patients with mg m(-2) advanced non-small-cell lung cancer (NSCLC). Of 31 patients assessable for response, one attained a complete remission and eight a partial remission, an overall response rate of 29%. Haematological toxicity was minimal, with only 3% of patients developing WHO grade III/IV neutropenia and 13% grade III/IV thrombocytopenia. Significant side-effects included moderate to severe emesis (41%), mucositis (34%), diarrhoea (31%) and palmar-plantar syndrome (14%). Seven patients (23%) had Hickman line complications requiring line removal. Continuous infusional chemotherapy with this regimen is active in advanced non-small-cell lung cancer, but its complexicity and associated treatment toxicity offer little advantage over equally active but simpler and less toxic cisplatin-based regimens.

Original publication




Journal article


British Journal of Cancer

Publication Date





1315 - 1318


infusional chemotherapy non-small-cell lung cancer mcf bronchogenic-carcinoma randomized trial chemotherapy polychemotherapy etoposide regimens